Therapeutic Response

CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in combination with Cisplatin, Cytarabine, and Etoposide in patients with Hodgkin Lymphoma.

Statements

Source and description

Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP). NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin in combination with ESHAP (etoposide, cisplatin, and cytarabine) (BRESHAP) for reimbursement as a treatment option for the treatment of adult patients with relapsed/refractory CD30+ Hodgkin's lymphoma.